Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4239-4247

  Yang, Hank H ^a   Ma, Mark H ^a   Vescio, Robert A ^a   Berenson, James R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; DAUNORUBICIN; EPIPODOPHYLLOTOXIN; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; TOPOTECAN; VINBLASTINE; VINCA ALKALOID; PROTEINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER RELAPSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MULTIDRUG RESISTANCE; NEOPLASM; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; P-GLYCOPROTEIN; PROTEASE INHIBITORS;

EID: 0642378063     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.001     Document Type: Article

References (92)

1. Dalton WS: Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 34:3-8, 1997
2. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427, 1993
3. Cole SP, Bhradwaj G, Gerlach JH, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654, 1992
4. Litman T, Brangi M, Hudson E, et al: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011-2021, 2000
5. Scheffer GL, Schroeijers AB, Izquierdo MA, et al: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550-556, 2000
6. Sellers WR, Fisher DE: Apoptosis in cancer drug targeting. J Clin Invest 104:1655-1661, 1999
7. Wang CY, Cusack JC, Liu R, et al: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5:412-417, 1999
8. Muller M, Meijer C, Zaman GJ, et al: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A 91:13033-13041, 1994
9. Borst P, Evers R, Kool M, et al: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302, 2000
10. Klein I, Sarkadi B, Varadi A: An inventory of the human ABC proteins. Biochim Biophys Acta 1461:237-262, 1999
11. Kitazono M, Sumizawa T, Takebayashi T, et al: Multidrug resistance and the lung resistance related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91:1647-1653, 1999
12. Dalton WS, Jove R: Drug resistance in multiple myeloma: Approaches to circumvention. Semin Oncol 26:23-27, 1999
13. Grogan TM, Spier CM, Salmon SE, et al: P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 81:490-495, 1993
14. Cornelissan J, Sonneveld P, Schoester M, et al: MDR1 expression and response to vincristine, doxorubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oneol 12:115-119, 1994
15. Lynsenmeyer ME, Jefferson S, Wolf M, et al: Levels of expression of the mdr 1 gene and glutathione-S-transferase genes 1 and 2 and response to chemotherapy in multiple myeloma. Br J Cancer 65:471-475, 1992
16. Marie JP: Drug resistance in hematologic malignancies. Curr Opin Oncol 13:463-469, 2001
17. Ross DD: Novel mechanisms of drug resistance in leukemia. Leukemia 14:467-473, 2000
18. Ross DD, Yang W, Abruzzo LV, et al: Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91:429-433, 1999
19. Lokhorts HM, Izquierdo MAI, Raaijmakers MGP, et al: Lung-resistance protein expression is a negative predictive factor for response to alkylating chemotherapy and survival in multiple myeloma. Blood 88:640a, 1996 (suppl)
20. Rimsza LM, Campbell K, Dalton WS, et al: The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. Leuk Lymphoma 34:315-324, 1999
21. Fisher GA, Lum BL, Hausdorff J, et al: Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32a:1082-1088, 1996 (abstr)
22. Dalton WS, Crowley JJ, Salmon SS, et al: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study. Cancer 75:815-820, 1995
23. Berenson JR, Crowley JJ, Grogan TM, et al: Maintenance therapy with alternative-day prednisone improves survival in multiple myeloma patients. Blood 99:3163-3168, 2002
24. Sonneveld P, Marier JP, Huisman C, et al: Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet 340:255-259, 1992
25. Archinal Mattheis A, Rzepka RW, Watanabe T, et al: Analysis of the interactions of SDZ PSC 833 ([3′keto-BMTI)-Val2]cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7:603-610, 1995
26. Boote DJ, Dennis IF, Twentyman PR, et ai: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618, 1996
27. Lum BL, Fisher GA, Brophy NA, et al: Clinical trials of modulation of resistance: Pharmacokinetics and pharmacodynamics considerations. Cancer 72:3502-3514, 1993
28. Greenberg P, Advani R, Tallman L, et al: Treatment of refractory/ relapsed AML with PSC 833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC vs MEC): Randomized phase III trial. Blood 94:383a, 1999 (abstr)
29. Baer MR, George SL, Dodge RK, et al: Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia (AML) patients 60 years old: Correlation of outcome with functional MDR. Blood 98:461a, 2002 (abstr)
30. Beck WT: Mechanism of multidrug resistance in human tumor cells: The role of P-glycoprotein, DNA topoisomerase II and other factors. Cancer Treat Rev 17:11-20, 1990
31. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
32. Fulda S, Susin S, Kroemer G, et al: Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 58:4453-4460, 1998
33. Solay E, Droin N, Bettaieb A, et al: Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 14:1833-1849, 2000
34. Wang CY, Mayo MW, Baldwin AS: TNF-alpha and cancer therapy-induced cell death. Science 274:784-787, 1996
35. Baldwin AS: The NF-kappa-B and iota-kappa-B proteins: New discoveries and insights. Annu Rev Immunol 14:649-681, 1996
36. Barkett M, Gilmore T: Control of apoptosis by Rel/NF-kappa-B transcription factors. Oncogene 18:6910-6924, 1999
37. Karin M, Lin A: NF-B at the crossroad of life and death. Nat Immunol 3:221-227, 2000
38. Hinz M, Krappman D, Eichten A, et al: NF-kappa-B function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690-2698, 1999
39. Berenson JR, Sjak-Shie N, Vescio RA: The role of human and viral cytokines in the pathogenesis of multiple myeloma. Semin Cancer Biol 10:383-391, 2000
40. Ghosh S, May M, Kopp E: NF-B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260, 1998
41. Takeshita H, Yashizaki T, Miller WE, et al: Matrix metalloproteinase 9 expression in induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 73:5548-5555, 1999
42. Koch AE, Polverini PJ, Kunkel SL, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801, 1992
43. Huang S, Robinson JB, Deguzman A, et al: Blockade of NF-kappa-B signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Cancer Res 60:5334-5339, 2000
44. Evan GL, Wyllie AH, Gilber CS, et al: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128, 1992
45. Zingarelli B, Hake PW, Yang Z, et al: Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappa-B and AP-1 activation and enhances myocardial damage. FASEB J 16:327-342, 2002
46. Li Q, Van Antwerp D, Mercurio F, et al: Severe liver degeneration in mice lacking the iota-kappa-B kinase 2 gene. Science 284:321-325, 1999
47. Finco T, Westwick JK, Norris JL, et al: Oncogenic Ha-Kas-induced signaling activates NF-kappa-B transcriptional activity which is required for cellular transformation. J Biol Chem 272:24113-24116, 1997
48. Ma HM, Parker KM, Manyak S, et al: Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144, 2003
49. Teicher BA, Ara G, Herbst R, et al: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638-2645, 1999
50. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622, 1999
51. Orlowski RZ, Eswara JR, Lafond-Walker A, et al: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348, 1998
52. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
53. LeBlanc R, Catley L, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. Blood 98:774a, 2001 (abstr)
54. Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 18:109-121, 2000
55. Richardson, PG, Berenson J, Irwin D, et al: Phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
56. Bargou R, Emmerich F, Krappmann D, et al: Constitutive activation of NF-kappa-B-RelA is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100:2961-2969, 1997
57. Sovak MA, Bellas RE, Kim DW, et al: Aberrant nuclear factor-B/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952-2960, 1997
58. Wu M, Lee H, Bellas RE, et al: Inhibition of NF-B/Rel induces apoptosis of murine B cells. EMBO 15:4682-4690, 1996
59. Cusack J, Liu R, Baldwin A: NF-kappa-B and chemoresistance potentiation of cancer chemotherapy via inhibition of NF-kappa-B. Drug Resist Updat 2:271-273, 1999
60. Wang CY, Cusack J, Liu R, et al.: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa-B. Nat Med 4:412-417, 1999
61. Cusack J, Liu R, Baldwin A: Inducible chemoresistance to CPT-11 in colorectal cancer cells and a xenograft model is overcome by inhibition of NF-kappa-B. Cancer Res 60:1323-1330, 2000
62. Huang Y, Johnson K, Norris J, et al: NF-kappa-B/IB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60:4426-4432, 2000
63. Betz R: Glucocorticosteroids and ambroxol inhibit secretion of inflammatory cytokines in tracheobronchial epithelial cells: Possible role of the NF-kappa B transcription factor. Pneumologie 51:491-492, 1997
64. Kapahi P, Takahashi T, Natoli G, et al: Inhibition of NF-kappa-B activation by arsenite through reaction with critical cysteine in the activation loop of iota-kappa-B kinase. J Biol Chem 275:36062-36066, 2000
65. Sordet O, Rebe C, Leroy I, et al: Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 97:3931-3940, 2001
66. Tang B, Bajenova O, Feinman-Siegal R, et al: Arsenic compounds induce apoptosis in multiple myeloma (MM), activate pro-caspase-3 but not affect BCL2 family members. Blood 92:638a, 1998 (suppl 1)
67. Mahieux R, Pise-Maison C, Gessain A, et al: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2- infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98:3762-3769, 2001
68. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360, 1997
69. Friedman JM, Ma MH, Manyak S, et al: Arsenic trioxide cause apoptosis, growth inhibition and increased sensitivity of chemotherapeutic agents in multiple myeloma cells through inhibition of nuclear factor (NF)-kappa-B activity. Proc Am Assoc Cancer Res 43:4585, 2002
70. Martinou JC, Green DR: Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63-67, 2001
71. Zamzami N, Kroemer G: The mitochondrion in apoptosis: How Pandora's box opens. Nat Rev Mol Cell Biol 2:67-71, 2001
72. Degterev A, Boyce M, Yuan J: The channel of death. J Cell Biol 155:695-698, 2001
73. Adams JM, Cory S: The bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326, 1998
74. Pettersson M, Jernberg-Wiklund H, Larssin L-G, et al: Expression of bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79:495-502, 1992
75. Gazitti Y, Liu Q, Vesole D, et al: Bcl-2 antisense oligonucleotide (ASO) enhances apoptosis and cytotoxicity in drug-resistant myeloma cells. Blood 98:641a, 2001 (abstr)
76. Wuchter C, Karawajew L, Ruppert V, et al: Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, mutation stage, and cytogenetics. Leukemia 13:1943-1953, 1999
77. Herrmann JL, Briones F Jr, Brisbay S, et al: Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogens 3:2889-2899, 1998
78. An B, Goldfarb RH, Siman R, et al: Novel dipeptidyl proteasome inhibitors overcomes Bcl-2 protective function and selective accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed but not normal human fibroblasts. Cell Death Differ 12:1062-1075, 1998
79. Feinman R, Gangurde P, Miller S, et al: Proteasome inhibitor PS341 inhibits constitutive NF-B activity and bypasses the anti-apoptotic bcl-2 signal in human multiple myeloma cells. Blood 98:640a, 2001 (abstr)
80. Chauhan D, Kharbands S, Ogata A, et al: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89:227-234, 1997
81. Ogata A, Chauhan D, Teoh G, et al: IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 159: 2212-2221, 1997
82. Lichtenstein A, Tu Y, Fady C, et al: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248-255, 1995
83. Wang W, Chen JX, Liao R: Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22:3389-3403, 2002
84. Peters R, Leyvraz S, Perey L: Apoptotic regulation in primitive hematopoietic precursors. Blood 92:2041-2052, 1998
85. Wierenga AT, Schuringa JJ, Eggen BJ: Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-beta1 is mediated by caspase-dependent and -independent processes. Leukemia 16:675-682, 2002
86. Epling-Burnette PK, Liu JH, Catlett-Falcone R: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107:351-362, 2001
87. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-115, 1999
88. Damiano JS, Cress AE, Hazlehurst LA, et al: Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658-1667, 1999
89. Damiano JS, Dalton WS: Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 38:71-81, 2000
90. Uchiyama H, Barut BA, Chauhan D, et al: Characterization of adhesion molecules on human myeloma cell lines. Blood 80:2306-2314, 1992
91. Stewart MP, Hogg N: Regulation of leukocyte integrin function: Affinity vs. avidity. J Cell Biochem 61:554-561, 1996
92. Stewart MP, McDowell A, Hogg N: LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain. J Cell Biol 140:699-707, 1998